secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001689375-26-000027
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada reports positive Phase 1/2 data for ENTR-601-44 in DMD; Q1 net loss $39.7M
--------------------------------------------------------------------------------

- Cohort 1 of ELEVATE-44-201 met primary safety endpoint: no SAEs, no discontinuations, kidney markers normal.
- Statistically significant improvement in Time to Rise velocity versus placebo (p<.05), 3.5x MCID threshold.
- Dystrophin increased 2.36% over 4.00% baseline; exon skipping increased 2.31% over 2.66% baseline.
- Cash, cash equivalents and marketable securities $254.9M as of March 31, 2026; runway into Q3 2027.
- Q1 net loss $39.7M vs $17.3M in Q1 2025; collaboration revenue dropped to $0.9M from $20.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/0001689375-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937526000027/trda-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001689375-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer